# OnCo record nct05945823 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05945823/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05945823", "NCT05945823" ;
  schema:name "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors"@en ;
  schema:description "A phase 2 trial of Futibatinib, Pembrolizumab, Cisplatin and Oxaliplatin in oesophageal cancer and pancreatic ductal adenocarcinoma, run by Taiho Oncology, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05945823/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05945823> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-07-13" ;
  onco:cancers <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/futibatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/oxaliplatin/> ;
  onco:companies <https://onco.cc/companies/araris/> .